TriOptoTec
Financials
Estimates*
EUR | 2020 | 2021 |
---|---|---|
Revenues | <1m | 3.4m |
% growth | - | 370 % |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | - | ||
Total Funding | - |
Related Content
Recent News about TriOptoTec
EditDyphox, a spin-off from the University Hospital Regensburg established in 2010, specializes in antimicrobial surface technologies designed to enhance hygiene in healthcare and office environments. The company operates in the healthcare and commercial sectors, providing innovative coating solutions that sterilize surfaces efficiently and close hygiene gaps. Dyphox's primary clients include hospitals, care facilities, and offices that require stringent hygiene standards. The business model revolves around the development and application of antimicrobial coatings, which are sold directly to institutions or through partnerships with manufacturers of office furnishings and medical equipment. Revenue is generated through the sale of these coatings and related services. Dyphox holds seven international patents, underscoring its commitment to research and innovation in antimicrobial technology.
Keywords: antimicrobial, surface technology, healthcare, hygiene, coatings, hospitals, care facilities, office environments, patents, innovation.